American Well Corporation filings document the company’s SaaS-based technology-enabled healthcare platform, operating results, customer agreements, governance, and equity-compensation structure. Its Form 8-K filings include earnings reports for quarterly and annual periods, material definitive agreements, board changes, and related exhibit disclosures.
AMWL filings also describe commercial arrangements tied to digital care delivery, including the company’s operation of a white-labeled platform under the LiveHealth Online brand for Elevance Health and related clinical-provider access through Online Care Group. Proxy materials cover director elections, executive compensation, equity awards, stockholder voting matters, and board governance for the public company.
American Well Corp (AMWL) reported third-quarter 2026 revenue of $49.0 million, down from $56.3 million a year earlier; nine-month revenue was $155.9 million versus $194.0 million. Subscription revenue declined, primarily because of the timing of revenue recognition with strategic customers. Platform visits in the first nine months fell to 2.7 million from 3.6 million; the company cited customer churn in urgent-care and behavioral visits and lower summer seasonal illness volume.
Net loss attributable to American Well narrowed to $11.4 million in Q3 from $32.4 million, and to $32.2 million for nine months from $70.8 million. Operating cash used for nine months was $1.9 million, versus $48.6 million. Cash and cash equivalents were $180.8 million at September 30, 2026. The company abandoned its corporate headquarters and recorded a $3.4 million right-of-use asset impairment; the lease remained in place, with rent payments due over its remaining term.
American Well Corp reported third-quarter 2026 revenue of $48.991 million, compared with $56.286 million in the year-earlier quarter. Subscription revenue was $23.9 million and Amwell Medical Group visit revenue was $23.7 million; gross margin was 53%, and platform visits totaled 0.8 million. Net loss was $10.958 million versus $31.911 million, while adjusted EBITDA loss was $3.598 million versus $12.669 million. Both losses were greater than in Q2 2026: net loss was $9.625 million and adjusted EBITDA loss was $1.150 million.
Amwell raised 2026 revenue guidance to $204 million-$206 million from $200 million-$205 million and adjusted EBITDA guidance to ($8) million-($7) million from ($9) million-($7) million; AMG visit guidance remains 1.32 million-1.37 million. Q4 guidance is revenue of $48 million-$50 million and adjusted EBITDA of $0-$1 million. The company reiterated its objective to achieve positive cash flow from operations in Q4. For the nine months ended September 30, 2026, operating cash use was $1.934 million, compared with $48.598 million in the 2025 period.
American Well Corp (AMWL) President, International Phyllis Gotlib sold 6,677 Class A common shares at $13.00 per share on October 1, 2026. The sale was an automatic “sell to cover” transaction to pay tax liability arising from the vesting and settlement of restricted stock units, and did not represent a discretionary trade. After the sale, she directly held 142,504 shares; 114,920 shares were held indirectly by her husband. No Rule 10b5-1 plan is reported.
American Well Corp (AMWL) Chief Financial Officer Mark Hirschhorn sold 4,282 shares of Class A Common Stock on October 1, 2026, at $13 per share. The shares were sold automatically to pay the tax liability arising from the vesting and settlement of restricted stock units; the transaction was not a discretionary trade. His direct holdings after the sale were 223,906 shares.
American Well Corp (AMWL) Chief Product & Tech. Officer Dmitry Zamansky sold 8,442 Class A common shares on October 1, 2026, at $13.00 per share. His reported direct holdings after the sale were 224,178 shares. The sale was an automatic “sell to cover” transaction, not a discretionary trade, and no Rule 10b5-1 plan is reported.
American Well Corp (AMWL) Chief Accounting Officer Paul Francis McNeice sold 653 shares at $13 per share on October 1, 2026. The sale was an automatic “sell to cover” transaction to pay tax liability arising from the vesting and settlement of restricted stock units, and was not a discretionary trade. McNeice directly held 9,086 shares following the sale.
American Well Corp (AMWL) lists Officer Mark Hirschhorn's planned sale of 4,282 Class A common shares on October 1, 2026, with an aggregate market value of $55,668.14. The remarks say the automatic “sell to cover” transaction is to pay tax liability from restricted stock unit vesting and settlement, and is not a discretionary trade. The notice also lists 6,302 shares associated with an RSU grant vesting October 1, 2026, and prior sales of 10,751 shares on September 1 and 4,299 shares on July 1, 2026.
American Well Corp (AMWL) officer Dmitry Zamansky reported 8,442 Class A common shares for sale, with an aggregate market value of $109,750.22 and an approximate sale date of October 1, 2026. The securities relate to vesting of an 18,133-share restricted stock unit grant. Zamansky said the sale is an automatic “sell to cover” transaction to pay taxes from the vesting and settlement, not a discretionary trade. In the prior three months, he reported sales of 8,460 shares for $78,944.49.
American Well Corp (AMWL) officer Phyllis Gotlib reported a proposed sale of 6,677 Class A shares on October 1, 2026, with an aggregate market value of $86,804.34. The notice also lists 12,680 shares associated with vesting of a Restricted Stock Unit Grant. Gotlib stated the sale is an automatic sell-to-cover transaction to pay taxes arising from the vesting and settlement of restricted stock units, not a discretionary trade.
American Well Corp (AMWL) reported that its Chief Financial Officer Mark Hirschhorn sold 10,751 shares of Class A common stock on September 1, 2026 at $11.80 per share. According to the disclosure, this automatic sell to cover transaction was executed solely to pay taxes on vested restricted stock units, and he continued to hold 228,188 shares directly afterward.